Ayrton Capital’s BioRestorative Therapies BRTX Stock Holding History

Ayrton Capital’s Portfolio BRTX Stock Details BRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-41,374	Closed	-$114K	–	87
2022 Q4	$114K	Sell	41,374 -20,044	-33%	-$62.4K	0.31%	31
2022 Q3	$198K	Hold	61,418	–	–	0.35%	40
2022 Q2	$181K	Sell	61,418 -16,344	-21%	-$69.3K	0.29%	44
2022 Q1	$407K	Sell	77,762 -35,000	-31%	-$151K	0.53%	50
2021 Q4	$489K	Buy	+112,762	New	+$644K	0.46%	55

Other funds holding BRTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ayrton Capital's BRTX Position: Q1 2023 in Review

Ayrton Capital sold out of BioRestorative Therapies (BRTX) in Q1 2023, closing a stake of 41,374 shares — an estimated $114K sold.

Ayrton Capital first reported a position in BRTX in Q4 2021 and held it in 5 quarters. The position peaked at $489K in Q4 2021. 14 funds tracked by Wall St. Rank hold BRTX as of Q1 2023.

Ayrton Capital reported no remaining BioRestorative Therapies position as of Q1 2023 after selling out during the quarter.
Ayrton Capital sold 41,374 BioRestorative Therapies shares in Q1 2023, an estimated $114K.
Ayrton Capital first reported a position in BioRestorative Therapies in Q4 2021 and held it in 5 quarters.
Ayrton Capital's BioRestorative Therapies position peaked at $489K in Q4 2021.
14 funds tracked by Wall St. Rank held BioRestorative Therapies as of Q1 2023.

Based on Ayrton Capital's 13F filing for Q1 2023, filed 12 May 2023.